Online inquiry

IVTScrip™ mRNA-Anti-EPHA3, KB-004(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9923MR)

This product GTTS-WQ9923MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets EPHA3 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_005233.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2042
UniProt ID P29320
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EPHA3, KB-004(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ9923MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7920MR IVTScrip™ mRNA-Anti-CSF2, GSK3196165(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA GSK3196165
GTTS-WQ405MR IVTScrip™ mRNA-Anti-ANGPT2, 2xCon4C(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA 2xCon4C
GTTS-WQ12280MR IVTScrip™ mRNA-Anti-CD274, MSB-0010718C(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MSB-0010718C
GTTS-WQ10217MR IVTScrip™ mRNA-Anti-RHD, LFB-R593(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA LFB-R593
GTTS-WQ12596MR IVTScrip™ mRNA-Anti-F11, NVS250519(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA NVS250519
GTTS-WQ3659MR IVTScrip™ mRNA-Anti-F11, BAY 1213790(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BAY 1213790
GTTS-WQ275MR IVTScrip™ mRNA-Anti-CD37, 177lu-DOTA-HH1(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA 177lu-DOTA-HH1
GTTS-WQ4863MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, BTCT4465A(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BTCT4465A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW